Same-day HPV self-testing with digital cytology triage in Cameroon
Official title: Evaluation of Digital Cytology for the Triage of HPV-positive Women in a Same-day "Test-triage-treat" Cervical Cancer Screening Strategy in Cameroon
Run by University Hospital, Geneva · NCT07550010 · Data updated 2026-11-12
This project will test whether HPV self-sampling followed by same-day digital telecytology can quickly find which HPV-positive women aged 30–49 (25–49 if HIV-positive) in Cameroon need treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 50 Years |
| Sex | Women only |
| Enrollment | 1800 (estimated) |
| Sponsor | University Hospital, Geneva Academic / other |
| Locations | 2 sites (Yaoundé and 1 other locations) |
| Status | Recruiting |
| Started | September 8, 2025 |
| Main results expected | September 8, 2026 |
| Study ends | September 8, 2027 |
| Registry record updated | April 24, 2026 |
| Trial ID | NCT07550010 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women living in or near Yaoundé who are 30–49 years old (25–49 if HIV-positive), able to consent, and able to attend same-day clinic procedures are ideal candidates.
✕Probably not a fit
Women who are HPV-negative, pregnant, have a prior hysterectomy, known cervical cancer, or conditions that prevent visualization of the cervix are excluded and would not benefit from this screening pathway.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective diagnostic accuracy and feasibility study at Yaoundé University Teaching Hospital using rapid HPV testing (GeneXpert) on self-collected samples. HPV-positive women are managed by an extended genotyping algorithm that directs immediate treatment for HPV16, same-day digital telecytology triage for several high-risk types, or follow-up for lower-risk types. Triage procedures include visual inspection with acetic acid (VIA), cytology, endocervical sampling, and biopsy as indicated, with histology as the reference standard for CIN2+. Secondary objectives include evaluating AI-assisted telecytology and the acceptability of screening and treatment strategies among women and providers.
Why it matters
Potential benefit: If successful, this approach could shorten the time to diagnosis and enable same-day treatment, reducing missed follow-up and progression to high-grade lesions.
How similar studies have gone: HPV self-sampling and test-triage-treat approaches have shown promise in low-resource settings, while AI-assisted and digital telecytology methods are newer and still undergoing validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old * Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF). Exclusion Criteria: * Pregnancy at the time of screening * Previous hysterectomy * Known cervical cancer * Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass) * Conditions that can interfere with visualization of the cervix * Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure) * Women who are not able to comply with the study protocol.
Where it's running
-
Centre Hospitalier Universitaire de Yaoundé
Yaoundé, Cameroon Recruiting -
Yaoundé University Teaching Hospital (CHU)
Yaoundé, Cameroon Recruiting
Study contacts
- Study coordinator: Patrick Petignat, Doctor; Professor
- Email: patrick.petignat@hug.ch
- Phone: +41 22 37 24 432
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lived experiences of women with HPV infection
This study talks with women who have HPV to hear in their own words how the infection affects daily life, relationships, and what information or support they wish they had.
-
Low-thermal Argon Plasma Devitalization for CIN2 Treatment
This study tests whether a low-thermal argon plasma treatment can heal CIN2 on the cervix better than a sham procedure or active surveillance in women aged 18–40.
-
Point-of-care triage and thermal treatment for cervical precancer with the IRIS device
This project tests a portable thermal ablation device plus an AI image triage tool to treat and prioritize HPV-positive women aged 30–49 with cervical precancer in El Salvador.
-
Self-collected HPV testing to help prevent cervical cancer
This trial tests whether people referred for colposcopy can collect their own vaginal sample for HPV testing and whether those self-samples match clinician-collected cervical samples.
-
Improving the Pap test experience to boost cervical screening participation
This trial will test whether adding a gentle, non-painful step at the end of a Pap test reduces remembered pain and increases future cervical cancer screening among women aged 25 and older.
-
Improving HPV vaccination rates among Latino adolescents in health centers
This study is testing new ways to help healthcare providers encourage Latino teens to get the HPV vaccine in health centers that serve their communities.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.